Photo: Courtesy of Glenmark Pharamaceuticals Ltd.

18 May 2015Asia

Indian Supreme Court stops Glenmark from making generic Januvia

The Supreme Court of India has ordered Glenmark Pharmaceuticals to stop making generic versions of Merck Sharp & Dohme’s diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird